Circulating endothelial cells as a marker of endothelial dysfunction in patients with psoriatic arthritis
Abstract. Psoriatic arthritis (PsA) is a chronic progressive inflammatory disease that involves damage of the skin and joints and leads to the development of cardiopulmonary diseases. Mortality among this cohort is 1.28 times higher than the population level. The presence of a prolonged systemic inflammatory process is a significant predictor of the development of cardiovascular (CV) diseases due to the progression of endothelial dysfunction (ED). Objective. To evaluate the role of circulating endothelial cell (CEC) levels as a marker of endothelial dysfunction in patients with psoriatic arthritis. Materials and Methods. We examined 97 patients diagnosed with PsA and 25 clinically healthy patients who formed the control group. All patients underwent diagnostic methods characterizing the course of the disease, assessment of endothelium-dependent vasodilation (EDVD) in response to reactive hyperaemia and CEC levels. Results. The results of the study of endothelial function in patients with PsA demonstrated that reduced EDVD (less than 10 %) was more common among patients with PsA compared to the control group (75.3 % vs. 11.8 %, respectively). The analysis of the CEC content in peripheral blood showed a significant difference (7.15 ± 0.19 and 4.05 ± 0.11, respectively, p < 0.001) between patients with PsA and the control group. In addition, were established the relationships between endothelial dysfunction and the state of endothelial vasodilatory function (rs = -0.91, p < 0.05), disease duration (rs = 0.69, p < 0.05), disease activity (DAPSA (rs = 0.65, p < 0.05), inflammatory process itself (ESR (rs = 0.39, p < 0.05), CRP (rs = 0.52, p < 0.05) and skin lesion prevalence (PASI (rs = - 0.42, p < 0.05)). Conclusions. Our studies suggest a significant prevalence of ED in patients with PsA. The high values of negative correlation between EDVD and CEC are quite expected and comparable to modern studies and allow us to consider desquamated endothelial cells as an independent marker for assessing the state of the endothelium in patients with PsA and are consistent with the literature.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019; 71 (1): 5–32. DOI: https://doi.org/10.1002/art.40726
Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res. 2019; 8: F1000 Faculty Rev-1665.
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–12. DOI: https://doi.org/10.1136/annrheumdis-2020-217159
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of Psoriasis: A Review. JAMA. 2020; 323 (19): 1945–60. DOI: https://doi.org/10.1001/jama.2020.4006
Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta‐analysis of observational studies. Journal of the American Heart Association. 2013;2(2):e000062. DOI: https://doi.org/10.1161/JAHA.113.000062
Zheng Z, Guo Q, Ma D, Wang X, Zhang C, Wang H, et al. Related risk factors and treatment management of psoriatic arthritis complicated with cardiovascular disease. Front Cardiovasc Med. 2022;9:835439. DOI: https://doi.org/10.3389/fcvm.2022.835439
Papagoras, C, Markatseli TE, Saougou I, Alamanos Y, Zikou AK, Voulgari P. et al. Cardiovascular risk profile in patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):57–63. DOI: https://doi.org/10.1016/j.jbspin.2013.03.019
Smiyan SI, Koshak BO, Gnatko IV. Endothelial dysfunction and cardiovascular risk in patients with Ankylosing spondylitis. IJMMR. 2017; 3(2): 5–9. DOI: https://doi.org/10.11603/ijmmr.2413-6077.2017.2.7935
Castellon X, Bogdanova V. Chronic inflammatory diseases and endothelial dysfunction. Aging Dis. 2016; 7(1): 81–9. DOI: https://doi.org/10.14336/AD.2015.0803
Ambrosino P, Bachetti T, D'Anna SE, Galloway B, Bianco A, D'Agnano V, et al. Mechanisms and clinical implications of endothelial dysfunction in arterial hypertension. J Cardiovasc Dev Dis. 2022; 9(5): 136. DOI: https://doi.org/10.3390/jcdd9050136
Tuleta, I., França, C. N., Wenzel, D., Fleischmann, B., Nickenig, G., Werner, N. et al. Intermittent hypoxia impairs endothelial function in early preatherosclerosis. Adv Exp Med Biol. 2015;858:1-7. DOI: https://doi.org/10.1007/5584_2015_114
Chimed S, van der Bijl P, Lustosa R, Fortuni F, Montero-Cabezas JM, Ajmone Marsan N, et al. Functional classification of left ventricular remodelling: prognostic relevance in myocardial infarction. ESC Heart Fail. 2022;9(2):912-24. DOI: https://doi.org/10.1002/ehf2.13802
Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric Oxide and Endothelial Dysfunction. Crit Care Clin. 2020;36(2): 307–321. DOI: https://doi.org/10.1016/j.ccc.2019.12.009
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115 (10): 1285–95. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.652859
Godo S, Shimokawa H. Endothelial Functions. Arterioscler Thromb Vasc Biol. 2017;37(9):e108-e114. DOI: https://doi.org/10.1161/ATVBAHA.117.309813
Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R, et al. Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients. Rev Recent Clin Trials. 2018; 13(3): 199–209. DOI: https://doi.org/10.2174/1574887113666180314105511
Erdbruegger U, Haubitz M, Woywodt A. Circulating endothelial cells: a novel marker of endothelial damage. Clin Chim Acta. 2006; 373(1–2): 17–26. DOI: https://doi.org/10.1016/j.cca.2006.05.016
Gendron N, Smadja DM. Circulating endothelial cells: a new biomarker of endothelial dysfunction in hematological diseases. Ann Biol Clin (Paris). 2016;74(4): 395–404. DOI: https://doi.org/10.1684/abc.2016.1160
Koshak BO. Serum levels of circulating endothelial cells as a marker of endothelial dysfunction in patients with ankylosing spondylitis. J. Clin. Exp. Med. Res. 2017; 5(3): 957–963.
Boos C, Soor S, Kang D. Relationship between circulating endothelial cells and thepredicted risk of cardiovascular events in acute coronary syndromes. Eur. Heart J. 2007; 28:1092–1101. DOI: https://doi.org/10.1093/eurheartj/ehm070
Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1): 55–78.
Hladovec J. Circulating endothelial cells as a sign of vessel wall lesions. Physiol Bohemoslov. 1978; 27(2): 140–4.
Flammer AJ, Lüscher TF. Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010; 459(6): 1005–13.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.